Table 4.

Transport and pharmacological properties of drugs *.

Symbol	Parameter	Unit	Bevacizumab	Liposome	Temozolomide
MW	Molecular weight	$\mathrm{g}·{\mathrm{mol}}^{-1}$	$1.49\times {10}^5$ [52]	$-$	$1.94\times {10}^2$ [53]
${\mathrm{P}}_{\mathrm{TV}}$	Transvascular permeability	$\mathrm{m}·{\mathrm{s}}^{-1}$	$-$	$5.8\times {10}^{-8}$ (T) [54] $0$ (N) [55]	$8.0\times {10}^{-8}$ (T) [56] $4.3\times {10}^{-8}$ (N) [56]
${\mathrm{D}}_{\mathrm{ECS}}$	Diffusivity in tissue ECS	${\mathrm{m}}^2·{\mathrm{s}}^{-1}$	$3.2\times {10}^{-13}$ (T) ‡ [8] $4.9\times {10}^{-14}$ (N) ‡ [8]	$1.5\times {10}^{-13}$ (T) [57] $3.2\times {10}^{-14}$ (N) [58]	$7.2\times {10}^{-10}$ (T) [31] $3.4\times {10}^{-10}$ (N) [59]
${\mathrm{K}}_{\mathrm{BC}}$	Binding constant of free drugs with proteins	$-$	$-$	$-$	$0.18$ [60]
${\mathrm{H}}_{\mathrm{CE}}$	CM/ECS partition coefficient	$-$	$-$	$-$	$1.5\times {10}^{-2}$ [61]
${\mathrm{H}}_{\mathrm{IE}}$	ICS/ECS partition coefficient	$-$	$-$	$-$	$1.0$ [62]
${\mathrm{k}}_{\mathrm{a}}$	Antiangiogenic rate	${\mathrm{M}}^{-1}·{\mathrm{s}}^{-1}$	$1.12$ ‡ [63]	$-$	$-$
${\mathrm{k}}_{\mathrm{e}}$	Elimination rate due to reactions	${\mathrm{s}}^{-1}$	$1.2\times {10}^{-5}$ [51]	$-$	$1.1\times {10}^{-4}$ [60]
${\mathrm{k}}_{\mathrm{rel}}$	Drug release rate	${\mathrm{s}}^{-1}$	$-$	$6.4\times {10}^{-4}$ [54]	$-$
${\mathrm{LD}}_{90}$	Drug dose that kills 90% of tumor cells	$\mathrm{M}$	$-$	$-$	$3.9\times {10}^{-5}$ [64]

* T and N stand for tumoral tissue and normal tissue, respectively. ^‡ Estimated based on the drug molecular weight.